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Abstract
Toll-like receptors (TLRs) are a family of highly conserved transmembrane proteins expressed in epithelial and immune cells that recognize
pathogen associated molecular patterns. Besides their role in immune response against infections, numerous studies have shown an important
role of different TLRs in cancer, indicating these receptors as potential targets for cancer therapy. We previously demonstrated that the activa-
tion of TLR3 by the synthetic double-stranded RNA analogue poly I:C induces apoptosis of androgen-sensitive prostate cancer (PCa) LNCaP
cells and, much less efficiently, of the more aggressive PC3 cell line. Therefore, in this study we selected LNCaP cells to investigate the mecha-
nism of TLR3-mediated apoptosis and the in vivo efficacy of poly I:C-based therapy. We show that interferon regulatory factor-3 (IRF-3) signal-
ling plays an essential role in TLR3-mediated apoptosis in LNCaP cells through the activation of the intrinsic and extrinsic apoptotic pathways.
Interestingly, hardly any apoptosis was induced by poly I:C in normal prostate epithelial cells RWPE-1. We also demonstrate for the first time
the direct anticancer effect of poly I:C as a single therapeutic agent in a well-established human androgen-sensitive PCa xenograft model, by
showing that tumour growth is highly impaired in poly I:C-treated immunodeficient mice. Immunohistochemical analysis of PCa xenografts
highlights the antitumour role of poly I:C in vivo both on cancer cells and, indirectly, on endothelial cells. Notably, we show the presence of
TLR3 and IRF-3 in both human normal and PCa clinical samples, potentially envisaging poly I:C-based therapy for PCa.
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Introduction
Prostate cancer (PCa) is the second most frequent diagnosed can-
cer among males worldwide and it is the sixth leading cause of
cancer-related deaths [1]. Standard therapy, consisting in surgical
excision of the prostate or radiation, initially leads to regression of
the disease, which however is often transient and no cure is known
for late stage PCa. Consequently, many efforts are being made to
identify novel molecular targets for the prevention and treatment of
this disease.
Toll-like receptors (TLRs) are a family of transmembrane pro-
teins that recognize pathogen associated molecular patterns, mole-
cules highly conserved in bacteria, viruses, fungi and parasites [2,
3]. TLRs are the key sensors of the innate immunity and are criti-
cally involved in priming the adaptive immune response necessary
for killing invading pathogens [4–6]. The first event of TLR signal
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transduction is the microbial ligand-induced TLR dimerization gen-
erating a TIR-TIR (Toll/Il-1 Receptor) domain interface able to
recruit adaptor proteins [7]. TLR3 signals specifically through TIR
domain-containing adaptor inducing interferon-b (TRIF), while the
other TLRs recruit the myeloid differentiation factor 88 (MyD88)
with the exception of TLR4 that signals through both TRIF and
MyD88 [3]. TLR ligands activate mitogen-activated protein kinases
(MAPKs) [8], NF-jB, interferon regulatory factors (IRFs) and other
transcription factors regulating proliferation and most of inflamma-
tion-linked genes [3].
Besides the canonical antimicrobial function of TLRs, it has been
demonstrated that these receptors are expressed in cancer epithelial
cells and involved in the control of tumour growth [9]. Interestingly,
although conflicting reports have been published concerning the pro-
or antitumoural role of several TLRs, most literature data agree on an
antitumour role for TLR3 [10, 11]. Different hypothetic functioning
modes for TLR3-dependent anticancer mechanism have been pro-
posed [12]: (i) An immune-mediated tumour growth suppression
[13], (ii) a direct apoptotic effect on TLR3 expressing cancer cells
[14–17], (iii) an inhibition of tumour growth through both immune-
mediated anticancer mechanisms and cancer cell apoptosis. Our
group has previously demonstrated that activation of TLR3 in PCa cell
lines induces the secretion of cytokines and chemokines that can
recruit and activate immune cells in the tumour site consequently
promoting their anticancer activity [18]. We have also shown that the
synthetic TLR3 agonist poly I:C inhibits the proliferation and induced
apoptosis in LNCaP and PC3 cells, with much higher efficiency in the
former than in the latter more aggressive line, depending on differen-
tial degree of up-regulation of the powerful tumour shield, hypoxia
inducible factor-1 [19]. In detail, poly I:C elicits inhibition of prolifera-
tion associated with a marked induction of TLR3-mediated apoptosis
in LNCaP cells through a PKC-a dependent mechanism upstream to
MAPK phosphorylation [15]. Nevertheless, several steps along this
pro-apoptotic signalling pathway still need to be clarified, in this work
we investigated other molecules involved in poly I:C-induced apopto-
sis in LNCaP cells and the in vivo efficacy of poly I:C-based cancer
therapy.
Toll-like receptor 3 is engaged by double-stranded RNA (dsRNA)
that represents either genomic or life cycle intermediates of many
viruses. In infected cells TLR3 ligands trigger the activation of
signalling pathways involved in antiviral responses, leading to
IRF-3-induced IFN production and NF-jB-induced cytokines and
chemokines secretion [20]. Focusing on IRF-3 activation, it has been
shown that dsRNA or poly I:C bind TLR3 promoting the interaction of
TRIF with TBK-1 and the resulting migration of phosphorylated IRF-3
into the nucleus [21, 22]. Then nuclear IRF-3 binds to interferon-
stimulated response elements promoting the transcription of type I
IFNs and other genes involved in immune response [23]. Besides its
key role in antiviral immunity, IRF-3-mediated apoptosis in response
to dsRNA was observed in melanoma and fibrosarcoma cells [24].
Our present data show that IRF-3 is a crucial player in poly I:C
induced apoptosis in LNCaP cells.
Moreover, we hypothesize a key role of direct apoptotic effect in
the antitumoural function of poly I:C in vivo regardless of the well-
known effectiveness of this compound as adjuvant in anticancer
immunotherapy [25]. In the present work, we verified this hypothesis
in PCa showing that subcutaneous growth of human LNCaP cells in
immunodeficient NOD scid gamma (NSG) mice was severely impaired
by treatment with poly I:C, thus demonstrating the direct anticancer
effect of the TLR3 agonist as a single therapeutic agent in human PCa
in vivo. Moreover, to evaluate the presence of TLR3-IRF-3 axis in the
human prostate we performed an immunohistochemistry analysis on
normal human prostate epithelium and PCa tissues. Expression of
TLR3 and IRF-3 was found in human prostate tissues both normal
and tumoural demonstrating that TLR3 signalling components are not
lost in PCa.
Materials and methods
Cell lines
Non-neoplastic adult human prostatic epithelial cells were immortalized
with human papillomavirus 18 leading to establishment of the RWPE-1
cell line [26].
RWPE-1 and LNCaP cell lines were obtained from American Type
Tissue Culture Collection (Rockville, MD, USA). LNCaP C4-2B were
kindly provided by Dr. Lien Spans (University of Leuven, Leuven, Bel-
gium).
RWPE-1 were maintained in keratinocyte SFM (serum-free medium)
supplemented with epidermal growth factor (5 ng/ml), bovine pituitary
extract (0.05 mg/ml; Gibco, Paisley, UK) and antibiotics (penicillin
10 U/ml and streptomycin 10 lg/ml). LNCaP were maintained in RPMI
medium supplemented with 2 mM L-glutamine, 100 IU/ml penicillin-
streptomycin and 10% foetal calf serum (FCS; Sigma-Aldrich, St Louis,
MO, USA). LNCaP cells at low passages (23–33) were used to perform
all the experiments. LNCaP C4-2B were maintained in DMEM-F12 med-
ium supplemented with 2 mM L-glutamine, 100 IU/ml penicillin-strepto-
mycin and 10% FCS. For signal transduction experiments, cells were
serum starved for 24 hrs and then stimulated with poly I:C in FCS-free
medium; otherwise, cells were treated in medium containing 3% FCS.
Reagents
Poly I:C was from Invivogen (San Diego, CA, USA). Z-IETD-FMK,
Z-LEHD-FMK and BX-795 were purchased from Merck-Millipore (Billerca,
MA, USA). Bicalutamide was purchased from Tocris Bioscience (Bristol,
UK). Unless otherwise specified reagents were purchased from Sigma-
Aldrich.
Immunofluorescence
Imaging of fluorescent markers was performed on cells grown on glass
coverslips. The nuclear translocation of IRF-3 was analysed in cells
treated for 4 hrs with 25 lg/ml poly I:C, then fixed in 4% paraformalde-
hyde, permeabilized with PBS/0.1% Triton X-100 and immunostained
with primary anti-IRF-3 polyclonal antibody (BD Biosciences, Milano,
Italy) followed by an Alexa Fluor 555-conjugated secondary anti-rabbit
antibody (Molecular Probes, Invitrogen, Eugene, Oregon, USA).
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Apoptosis assays
Propidium iodide (PI) staining: cells were detached with trypsin, washed
with cold PBS-5% FCS and then fixed in 70% ethanol for 24 hrs, at 4°C.
After washing with PBS, cells were incubated with 1 lg/ml PI for 3 hrs at
25°C before FACS analysis by Coulter Epics XL flow cytometer (Beckman
Coulter, Fullerton, CA, USA). Data were analysed by using FCS Express by
De Novo Software (Los Angeles, CA, USA). Cells were considered apopto-
tic when their DNA content was <2N after excluding debris.
AnnexinV staining: Cells were detached with trypsin, washed with
PBS–5% FCS and then placed in binding buffer containing 0.14 M NaCl,
2.5 mM CaCl2 and 0.01 M N-2-hydroxyethylpiperazine-N
0-2-ethanesulf-
onic acid (pH 7.4) to which Propidium Iodine and annexin V-FITC
(Immunological Sciences, Rome, Italy) were added prior to FACS analy-
sis following the manufacturer’s instructions. Annexin V-FITC positive
and P.I. negative cells were considered apoptotic.
siRNA silencing
Small interfering RNA duplex oligonucleotides complementary to the
30UTR of human IRF-3 (50-GGA CCA AGA GGC UCG UGA UGG UCA
A-30) and Noxa (50-GCA UUG UAA UUG AGA GGA AUG UGA A-30) were
synthesized and purchased from Integrated DNA Technologies (Coral-
ville, IA, USA). Transfection of 10 nM siRNA in LNCaP cells was carried
out with Oligofectamine Transfection Reagent, according to the manu-
facturer’s instructions. Complete fresh medium was added 5 hrs after
transfection and cells were further incubated for 42–72 hrs prior to pro-
ceeding with other treatments. Non-targeting control served as experi-
mental control.
Caspase activity assay
Caspase activity was evaluated using the caspase assay kit (BioVision,
Milpitas, CA, USA) as recommended by the manufacturer. LNCaP cell
lysates were evaluated for their ability to cleave substrates specific for
recognition by active caspase 8 (IETD-pNA) and caspase 9 (LEHD-pNA).
After 2–4 hrs at 37°C, samples were read with a plate reader (das,
Italy) at 405 nm.
Western blotting
Cell lysates were prepared in cell lysis buffer (Cell Signaling, Danvers,
MA, USA). Protein concentration was determined by the micro bicinch-
oninic acid method (Pierce, Rockford, IL, USA).
Equal amounts of proteins (25–40 lg) were subjected to SDS-PAGE
and transferred onto nitrocellulose membrane. Then membranes were
saturated with 5% non-fat dry milk in Tris-buffered saline with 0.1%
Tween-20 and incubated overnight with primary antibody at 4°C and
subsequently with horseradish peroxidase-conjugated secondary anti-
body for 1 hr at room temperature. Membranes were washed with Tris-
buffered saline with 0.1% Tween-20 after each antibody incubation and
developed by using the chemiluminescence system (ECL Advance;
Amersham Bioscience, Piscataway, NJ, USA). Source of primary anti-
bodies: anti-phospho-IRF-3, anti-TLR3 and anti-Cleaved Caspase 3 from
Cell Signaling (Beverly, MA, USA), anti-NOXA from Enzo Life Science
(Lausen, Switzerland) and b-actin antibodies from Sigma-Aldrich.
Horseradish peroxidase-conjugated goat antimouse or anti-rabbit Sec-
ondary antibodies were from Bio-Rad (Hercules, CA, USA).
In vivo model
Six to 10-week-old male NOD scid gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/
SzJ) mice were purchased from Charles River Laboratories (Calco, LC,
Italy) and housed in groups of four in isolated ventilated cages; food
and water were provided ad libitum. All animal procedures were per-
formed according to the protocol approved by the Istituto Superiore di
Sanita Animal Care Committee (DM No. 228/2009). 4 9 106 LNCaP
cells were resuspended in 100 ll PBS and mixed (1:1, vol/vol) with
growth factor reduced matrigel (BD Biosciences, San Jose, CA, USA).
The cells suspension was subcutaneously injected into the flank of
mice. Tumours were grown to ffi50–100 mm3 before beginning treat-
ment with poly I:C or vehicle (saline solution). Intraperitoneal or intra-
tumoural injection of 16 mg/kg poly I:C was performed 3 times weekly
for 3–4 weeks. Tumour volume based on calliper measurements were
calculated by the modified ellipsoidal formula (Tumour vol-
ume = ½ 9 (length 9 width2)).
Immunohistochemistry
Xenografts were harvested for histological analysis, embedded in OCT
frozen in liquid nitrogen and preserved at 80°C until sectioning.
After personal patient consent and Sant’Andrea Hospital Ethical
Comity approval, 30 human PCas blocks, 12 from radical prostatectomy
and 18 from diagnostic biopsies, from the histoteque of Sant’Andrea
Hospital Pathology Section of Clinical and Molecular Department of
‘Sapienza’ University of Rome, were chosen to have 10 cases with
Gleason score (as modified by WHO 2011) ≤6 (G1), 10 cases Gleason
score = 7 (G2), 10 cases Gleason score ≥8 (G3).
5 lm mouse tumours frozen sections, fixed with 100% acetone and
5 lm human cancer paraffin sections deparaffined and antigen retrieved
by using a pH9 Dako Retriever solution, were immunostained by a
DAKO Autostainer, with EnVisionTM FLEX+ revelation system (Dako Colo-
rado Inc, Fort Collins, Colorado, USA). Primary antibody Company,
Clones, Isotype and working dilutions are reported in Table S1.
Human PSA, Ki67 and AMACR were diluted and used as routinely
done during prostate adenocarcinoma diagnostic workout. For antibod-
ies against CXCR4, VEGF, IRF3, CD34, TLR3, Cl. Caspase 3, working
dilutions were established by using different frozen or/and formalin
fixed, paraffin embedded control tissues such as human reactive lymph
nodes for CXCR4, IRF3, TLR3 and active caspase-3, Placenta for VEGFA
and finally mouse lung for CD34. Negative controls were done by using
the respective control isotype antibodies (Table S1). Controls for the
secondary antibodies were done withdrawing the primary antibodies.
Tissues reactivity was finally compared with the THE HUMAN PROTEIN
ATLAS (http://www.proteinatlas.org/). Mouse derived tumour results are
reported as a mean + SD of the percentage of positive cells.
Statistical analysis
Differences between groups were analysed with a two-sided paired
or unpaired Student’s t-test by use of GraphPad Prism 5.00
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(GraphPadSoftware, San Diego, CA, USA). Results were considered to
be statistically significant if P < 0.05.
Results
Crucial role of IRF-3 in TLR3-mediated apoptosis
in LNCaP cells
The transcription factor IRF-3 plays a crucial role in dsRNA-induced
apoptosis of infected cells [27]. Therefore, we wondered whether
IRF-3 is also involved in TLR3-mediated apoptosis in the poly I:C-
sensitive PCa cells LNCaP. Firstly, we verified the activation of IRF-
3 in LNCaP stimulated with 25 lg/ml poly I:C for 4 hrs by evaluat-
ing the ability of IRF-3 to migrate to the nuclei by immunofluores-
cence analysis. IRF-3 was observed to co-localize with DNA stained
with Hoechst after poly I:C stimulation (Fig. 1A). IRF-3 activation
was also confirmed by western blot showing IRF-3 phosphorylation
in poly I:C-treated cells (Fig. 1B). Subsequently, we verified whether
poly I:C-induced IRF-3 activation is dependent on TLR3 or on dif-
ferent cytosolic receptors able to sense dsRNA and priming innate
immune response. To this aim, we pre-treated cells with an inhibi-
tor of endosome acidification (Bafilomycin A1), known to impair
TLR3 signalling. As expected, Bafilomycin A1 completely inhibited
poly I:C-induced IRF-3 phosphorylation (Fig. 1B). To further confirm
the exclusive role of TLR3 upstream IRF-3 phosphorylation, we
inhibited TRIF-1, a molecule which is found exclusively downstream
of TLR3, by pre-incubating cells with the membrane permeable
TRIF-1 inhibiting peptide (pepinh-TRIF) or a control peptide (pe-
pinh-CTR). Western blot analysis showed that, treatment with
25 lM pepinh-TRIF completely blocks poly I:C-induced phosphory-
lation of IRF-3 indicating that TLR3 triggers IRF-3 activation in
LNCaP cells (Fig. 1B).
To investigate the potential involvement of IRF-3 in TLR3-medi-
ated apoptosis we used BX-795, an inhibitor of TBK-1 (the kinase
responsible for IRF-3 activation), and evaluated its ability to inhibit
the apoptotic effect of poly I:C. PI staining showed that BX-795
pre-treatment significantly inhibits poly I:C-induced apoptosis.
Indeed, flow cytometry analysis showed a reduction of sub-G1
peak from 48.9  2.9% in poly I:C-treated cells to 23.4  5.2% in
cells pre-treated with BX-795 and stimulated with poly I:C
(Fig. 2A). To confirm the involvement of IRF-3 in poly I:C-induced
apoptosis, we performed specific knock-down of IRF-3 by small
interfering RNA in LNCaP cells and we observed that IRF-3 silenc-
ing strongly inhibits apoptosis in cells stimulated with poly I:C
compared to cells pre-treated with non-targeting siRNA (sub-G1
apoptotic cell population = 17.84% versus 35.74%; Fig. 2B). As a
control, we verified that BX-795 treatment inhibited poly I:C-
induced IRF-3 phosphorylation (Fig. 2C) and that targeting of IRF-3
by means of siRNA sequence massively reduced IRF-3 protein
expression, as shown in Figure 2D.
Moreover, we assayed cleaved caspase-3 levels in LNCaP cells in
which the activation or the expression of IRF-3 was pharmacologically
or genetically reduced. Western blot analysis showed that both IRF-3
phosphorylation inhibitor BX-795 and IRF-3 silencing strongly inhibit
caspase-3 cleavage (Fig. 2C and D), confirming the role of IRF-3 in
TLR3 mediated apoptosis in LNCaP cells.
Poly I:C triggers IRF-3-dependent extrinsic and
intrinsic apoptotic pathways
To determine whether in LNCaP cells poly I:C induces apoptosis
and triggers a caspase cascade through extrinsic and/or intrinsic
A
B
Fig. 1 Poly I:C induces IRF-3 activation in LNCaP cells. (A) LNCap cells
were stimulated with 25 lg/ml poly I:C (PIC) for 4 hrs and stained with
IRF-3 antibody (Red) and Hoechst (blue). Nuclear translocation of IRF-3
in PIC treated cell is shown. Original low magnification 400X, high mag-
nification 630X. (B) WB analysis showing the inhibition of PIC-induced
IRF-3 phosphorylation (Ser-396) by pre-treatment of LNCaP cells with
25 lM TRIF inhibiting peptide (pep-TRIF) or control peptide (pep-CTR)
or 100 nM Bafilomycin A1. b-actin was used as control for equal
amount of proteins loaded. Similar results were obtained in three inde-
pendent experiments.
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pathways, we evaluated the effect of the specific caspase 9 inhibi-
tor Z-LEHD-FMK or of the caspase 8 inhibitor Z-IETD-FMK in poly
I:C-induced apoptosis. As shown in Figure 3A and B, Z-LEHD-
FMK-treated poly I:C-stimulated LNCaP cells exhibited an apoptotic
rate reduction of 50%, whereas caspase 8 inhibitor appears to be
more effective in reducing poly I:C-induced apoptosis (67%). In
detail, sub-G1 apoptotic cell population in poly I:C plus Z-IETD-
FMK-treated cells is 11.2%  1.4% compared to 32.9%  3.5%
in cells treated with poly I:C alone. Therefore, to analyse the role
of IRF-3 in caspase activation we investigated the effect of the
TBK-1 inhibitor BX-795 on the activity of caspase 9 and 8 in
LNCaP cells. As expected, 25 lg/ml poly I:C increased activity
both of caspase 9 and 8 and 1 lM BX-795 treatment massively
reduced caspase 9 activity (O.D.: 0.131 versus 0.08), while slightly
reducing poly I:C-induced caspase 8 activity (O.D.: 0.192 versus
0.167; Fig. 3C). These data suggest that IRF-3 activation repre-
sents a critical step in caspase-8 and 9-mediated apoptotic path-
way, even though at different extent.
Noxa silencing increases TLR3-mediated
apoptosis
To assess the mechanism by which IRF-3 regulates TLR3-mediated
apoptosis, we examined the modulation of pro-apoptotic proteins in
LNCaP cells in which the activation or the expression of IRF-3 was
A
B
C
D
Fig. 2 IRF-3 regulates Poly I:C-induced
apoptosis in LNCaP cells. (A) 1 lM TBK-1
inhibitor BX-795 significantly reduced
apoptosis in LNCaP cells stimulated with
25 lg/ml poly I:C (PIC) for 24 hrs. (B)
IRF-3 silencing impaired apoptosis in
LNCaP cells stimulated with 25 lg/ml PIC
for 24 hrs (NT = non-targeting). (A and
B) Bar chart represents % of SubG1 cells
(mean  SEM) of three independent
experiments in duplicate (left panel)
*P < 0.006. Representative plots of cell
cycle analysis evaluated by flow cytometry
(PI staining) are shown (Right panel). The
range of apoptosis of Ctrl is 0–1%. (C
and D) LNCaP cells were treated with
25 lg/ml PIC for 24 hrs in the presence
of BX-795 (C) or following IRF-3 siRNA
(D). Whole cell lysates were analysed by
western blot with anti-IRF-3, anti-phos-
pho-IRF-3 and anti-Cleaved Caspase 3 (Cl.
Casp. 3) antibodies. b-actin was used as
control for equal amount of proteins
loaded. Similar results were obtained in
three independent experiments.
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pharmacologically or genetically altered. Despite the role of IRF-3 in
regulating type I IFN transcription, it has been shown that this tran-
scription factor also regulates the expression of pro-apoptotic pro-
teins involved in the intrinsic apoptotic pathway, such as Noxa [24].
Consistent with this evidence, we observed that Noxa is overexpres-
sed in poly I:C-treated LNCaP cells and that BX-795 treatment inhibits
Noxa induction (Fig. 4A), indicating Noxa as a potential pro-apoptotic
effector of TLR3 signal transduction via IRF-3. To better elucidate the
role of IRF-3 in this process silencing experiments were performed.
IRF-3 down-regulation inhibited the overexpression of Noxa induced
by poly I:C, confirming the essential role of IRF-3 in the control of
Noxa expression (Fig. 4A). Surprisingly, silencing of Noxa (Fig 4B)
A
B
C
Fig. 3 IRF-3 regulates PIC-induced caspase 8 and 9 activity. (A and B) Bar charts (left panel) represent % of SubG1 cells (mean  SEM) stimulated
with poly I:C (PIC) for 24 hrs in the presence or absence of caspase 9 (A) or caspase 8 (B) inhibitors. Results are from three independent experi-
ments in duplicate. Representative plots of cell cycle analysis evaluated by flow cytometry are shown (A and B, right panel); *P < 0.005;
**P < 0.0003. The range of apoptosis of Ctrl is 0–1%. C, BX-795 inhibits caspase 8 and 9 activity. Bar chart represents OD 405 nm (mean  SEM)
of three independent experiments; *P < 0.04, **P < 0.003.
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increased poly I:C-induced apoptosis in LNCaP cells, as shown in
Figure 4C.
LNCaP cells are more sensitive to poly I:
C-induced apoptosis than normal prostate
epithelial cells
To determine the selectivity of poly I:C, we evaluated its apoptotic
effect in normal prostate epithelial cells RWPE-1. Firstly, we showed
that TLR3 was expressed in RWPE-1 and LNCaP cells and up-regu-
lated in the two cell lines stimulated with poly I:C for 24 hrs (Fig. S1).
Subsequently, the ability of poly I:C to induce apoptosis was investi-
gated by means of flow cytometry. Annexin V-FITC/PI staining
showed that LNCaP cells were more sensitive to poly I:C-induced
apoptosis than RWPE-1 (annexin V-FITC+/PI: 16.34% versus 2.83%;
Fig. 5A). These data were confirmed by PI staining assay showing an
increase of sub-G1 peak (apoptotic cells) up to ffi30% in LNCaP cells
after 24 hrs treatment with 25 lg/ml poly I:C (P < 0.002; Fig. 5B).
Poly I:C-induced apoptotic rate rose in a remarkable dose-dependent
manner in LNCaP cells, whereas only slightly increased (less than
10%) in RWPE-1 cells (Fig. 5C).
Androgen sensitivity is crucial for poly I:
C-induced apoptosis in LNCaP cells
Since we have previously demonstrated that poly I:C induces a stron-
ger apoptosis in androgen-sensitive LNCaP cells compared with
androgen-insensitive AR negative PC3 and DU-145 cell lines [10, 15],
we treated LNCaP cells with androgen receptor (AR) inhibitor bicalu-
tamide to evaluate the potential contribution of androgen sensitivity
to poly I:C-induced apoptosis in LNCaP cells. Flow cytometry analysis
showed that when poly I:C-stimulated cells were also pre-treated with
10 or 20 lM bicalutamide, the sub-G1 peak was significantly reduced
as shown in Figure 5D. Moreover, the metastatic, androgen-insensi-
tive and AR positive LNCaP subclone C4-2B [28] resulted completely
unresponsive to poly I:C-induced apoptosis, as shown in Figure 5E.
In vivo TLR3-mediated inhibition of
tumour growth
To investigate the direct effect of poly I:C on tumour growth in vivo,
we inoculated LNCaP cells in NSG mice (lacking B, T and NK cells).
Our results show that tumour growth was severely impaired by both
intraperitoneal (Fig. 6A, C and E) and intratumoural (Fig. 6B, D and F)
poly I:C administration, demonstrating for the first time the direct
non-immune-mediated anticancer effect of the TLR3 agonist as a sin-
gle therapeutic agent in human PCa cells in vivo.
Intraperitoneal or intratumoural injection of 16 mg/kg poly I:C 3
times weekly for 3–4 weeks did not produce any adverse health
effects in mice as monitored by diet consumption, bodyweight loss
(Fig. 6G and H) and postural and behavioural changes.
The comparative histological analysis of poly I:C-treated and
untreated LNCaP tumours showed that both intraperitoneal and intra-
tumoural poly I:C administration affected the tumour features in a
comparable fashion. In detail, poly I:C-treated tumour cells appeared
unorganized, poorly cohesive and with large areas of necrosis, figures
usually related to a regressive context. To further examine whether
LNCaP tumours underwent cell cycle arrest and/or cell death follow-
ing treatment with Poly I:C, the expression of Ki-67, a marker of pro-
liferation and of the apoptotic marker cleaved caspase-3 were
assessed in the xenograft tumours. When compared to vehicle alone,
poly I:C treatment reduced the expression of Ki-67 and increased
cleaved caspase 3 staining (Fig. 7A and C), demonstrating the anti-
proliferative and pro-apoptotic effects of poly I:C in vivo. Moreover, in
accordance with our in vitro results, tumours treated with poly I:C
showed nuclear localization of IRF-3, confirming the activation of this
transcription factor in LNCaP xenografts (Fig. 7A and C). Immunohis-
tochemical analysis further showed that poly I:C treatment signifi-
cantly increased tumour cell PSA expression, while not affecting
AMACR and almost wiping out CXCR4 staining from cancer cells
(Fig. 7B and C). Finally, the analysis of angiogenesis markers showed
that poly I:C treatment was followed by a change in vessel morphol-
ogy, loss of well-structured walls and flimsy appearance and by a
massive reduction in the density of CD34 positive tumour vessels
(7  3 versus 19  5 vessels/mm2 of tumour surface, P < 0.0001;
A
B
C
Fig. 4 Noxa silencing increases TLR3-mediated apoptosis in LNCaP
cells. (A) western blot analysis showing the inhibitory effects of BX-795
(1 lM) and IRF-3 silencing on poly I:C-induced expression of Noxa. (B)
Western blot analysis after Noxa silencing in cells stimulated with poly
I:C for 4 hrs. b-actin was used as control for equal amount of proteins
loaded. (C) Evaluation of apoptosis by means of PI staining. Bar chart
represents % of SubG1 cells (mean  SEM) stimulated with PIC in
presence of non-targeting (NT) or Noxa siRNA (*P < 0.03). The range
of apoptosis of Ctrl is 0–3%.
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Fig. 7B and C). Consistent with this data was the concomitant reduc-
tion of VEGF staining in poly I:C-treated cancer cells (Fig. 7B and C).
These findings point towards a central role of poly I:C in the survival
and organization of endothelial cells in vivo.
Expression of TLR3 and IRF-3 in human PCas
To investigate TLR3 expression in human PCa and its association with
IRF-3 expression, sections from 30 human prostate samples, har-
bouring cancers of different grade (10 tumours G1 = Gleason score
≤6; 10 tumours G2 = Gleason score 7; 10 tumours G3 = Gleason
score ≥8) were immunostained with anti-TLR3 and anti-IRF-3 anti-
bodies. We found that both proteins were expressed in normal pros-
tate epithelium with a distribution, prevalent or limited, to the basal
cell layer (Fig. 8).
As reported in Table 1, 26 out of 30 tumours tested expressed
TLR3 while only one out of 30 different tumours was found negative
for IRF-3. TLR3- and IRF-3- positive cell number and staining inten-
sity was variable within the tumours but generally higher in PCa than
in normal prostate gland (namely 68% versus 43% TLR3-positive
cells and 83% versus 46% IRF-3-positive cells); moreover, the per-
centage of positive cells was found to significantly increase with the
worsening of the tumour grade. As expected, TLR3 staining was
cytoplasmatic and granular, while anti-IRF-3 stained diffusely the
cytoplasm (Fig. 8).
A B
C D E
Fig. 5 Poly I:C induces selectively apoptosis in androgen-sensitive prostate cancer cells. (A–C) Flow cytometric analysis of apoptosis. LNCaP and
RWPE-1 cells were stimulated with 25 lg/ml poly I:C (PIC) for 24 hrs and the percentages of apoptotic cells were determined by flow cytometry by
using Annexin-FITC/Propidium Iodide dual staining (PI; A) and SubG1 peak analysis after PI staining (B). (C) The histogram shows the apoptotic
effect of increasing doses of PIC in LNCaP and RWPE-1 cells evaluated by PI staining. PIC concentrations are expressed as lg/ml. Data represent
mean  SEM of three independent experiments. *P < 0.03, **P < 0.0005. (D) SubG1 peak analysis of LNCaP cells pre-treated 1 hr with 10 or
20 lM bicalutamide (Bic.) and then stimulated with 25 lg/ml PIC, as indicated. *P < 0.02, **P < 0.0065. (E) Histogram showing the effect of
25 lg/ml PIC in LNCaP C4-2B cells.
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Discussion
In this study, we demonstrate that the transcription factor IRF-3
plays an essential role in regulating TLR3-mediated apoptosis in
LNCaP cells mainly through the activation of both intrinsic and extrin-
sic apoptotic pathways. Moreover, we show for the first time the
direct anticancer effect of the synthetic TLR3 ligand poly I:C as a
single therapeutic agent in a well-established human PCa xenograft
model.
In infected cells viral dsRNA triggers the activation of specific
transcription factors, such as IRF-3, a critical player in the induction
of type I IFNs which inhibits virus replication (for a review see [29]).
Accordingly, we found that the stimulation of LNCaP cells with poly I:
C induces the migration of IRF-3 into the nucleus and its phosphory-
lation, known to be necessary for the transcriptional activity of this
protein. Moreover, both TRIF inhibitory peptide and bafilomycin com-
pletely impaired poly I:C-induced IRF-3 phosphorylation demonstrat-
ing the leading role of TLR3 in this process and excluding the
involvement of other dsRNA cytosolic receptors. These data confirm
that TLR3 is the main player in LNCaP response to poly I:C treatment,
as previously shown by our and other groups [15, 30]. In addition to
gene induction, virus infection can also trigger apoptosis and it has
been recently reported that apoptotic pathway activated by paramyxo-
virus infection is IRF-3-dependent [31]. The same IRF-3-dependent
A B
G H
C D
E F
Fig. 6 Poly I:C inhibits the growth of
LNCaP xenografts. LNCaP cells were sub-
cutaneously inoculated in NSG mice and
treated as indicated in Material and Meth-
ods. Analysis of tumour volume (A and B)
and tumour weight of (C and D) mice
injected intraperitoneal (i.p.) (A and C) or
intratumoural (i.t.) (B and D) with poly I:C
or saline and representative pictures of
tumours treated as indicated (E and F).
Graphs show the bodyweight of mice
bearing tumour xenografts treated with
i.p. (G) or i.t. (H) poly I:C or saline solu-
tion as indicated. Graph of a representa-
tive experiment (mean  SEM).
Comparable results were obtained in three
independent experiment for i.p. treatment
and two independent experiments for int-
ratumoural treatment. *P < 0.006;
**P < 0.002. Each group consists of min-
imum 6 mice.
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mechanism of poly I:C-induced apoptosis is effective also in human
fibrosarcoma cells [27]. Accordingly, here we demonstrate that the
inhibition of IRF-3 phosphorylation or expression, through BX-795 or
specific siRNA respectively, significantly impairs TLR3-mediated
apoptosis, highlighting a crucial role of IRF-3 in the regulation of
apoptosis in LNCaP cells. However, previous data have stated that
IRF3-dependent apoptotic pathway in both virus infected and cancer
cells is triggered only by the activation of dsRNA-sensing cytoplasmic
receptors and not by endosomal receptor TLR3. To our knowledge,
the present study demonstrates for the first time that IRF-3 is crucial
for the TLR3-mediated induction of the intrinsic and extrinsic apopto-
tic pathway in LNCaP cells in vitro. It is known that IRF-3 can induce
apoptosis through at least two different mechanisms. The first mech-
anism involves IRF-3-mediated transcription of the pro-apoptotic BH3
protein Noxa [32]. The second mechanism occurs through the direct
interaction of IRF-3 with the pro-apoptotic protein Bax, the conse-
quent migration of this protein-complex to mitochondria and the
resulting activation of the intrinsic apoptotic pathway [27, 33]. Never-
theless, our data suggest that even though IRF-3 regulates the tran-
scription of Noxa, silencing of Noxa not only fails to protect LNCaP
cells from poly I:C-induced apoptosis but surprisingly increases cell
death, in line with Weber et al. data in melanoma cells [34].Further
investigations are needed to better understand the molecular mecha-
nism of IRF-3-mediated apoptosis in PCa cells.
As previously shown in breast and melanoma cancer cell
lines [11, 16, 17], the pro-apoptotic effect of TLR3 signalling in PCa
is restricted to some cell types [15]. Here, we compared the effect of
poly I:C in the normal prostate epithelial cells RWPE-1, tumourigenic
A B
C
Fig. 7 Immunohistochemistry of LNCaP xenografts. (A and B) 10 PIC treated (i.p.) and 10 saline treated tumours from two independent experiments
were immunostained with the different antibodies. (C) Bar chart represents positive cells that were evaluated counting 10 high power fields (HPF).
Values are reported as mean  SD of the percentage of positive tumour cells of all the tumours. Mean number of vessels  SD per mm2 tissue is
shown.
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androgen-sensitive LNCaP cells and androgen-insensitive LNCaP-
derived C4-2B cells. The low sensitivity of RWPE-1 to poly I:C-
induced apoptosis demonstrates that non-tumourigenic prostate
epithelial cell viability is not markedly impaired by this treatment,
although TLR3 stimulation activates the canonical signal transduction
in this cell line (data not shown), therefore supporting the use of this
compound in vivo as anticancer therapy. Accordingly, Besch et al.
have previously shown that non-malignant epithelial cells are less
sensitive than melanoma cells to poly I:C-induced apoptosis and our
data support the hypothesis that TLR3-mediated apoptosis is selec-
tive for cancer cells also in the prostate [32, 35]. Among PCa cell lines
tested for the apoptotic effect of poly I:C, the AR negative PC3 and
Du-145 cells are resistant, whereas the AR positive LNCaP cells
undergo a strong apoptosis. Therefore, to evaluate the role of AR in
TLR3-mediated apoptosis we investigated the poly I:C effect in LNCaP
cells treated with AR antagonist bicalutamide and also in a model of
metastatic, castration resistant and AR positive PCa (LNCaP C4-2B
cells). We observed that treatment of LNCaP cells with bicalutamide
significantly reduced the apoptotic effect of poly I:C and that the
androgen-insensitive LNCaP C4-2B were completely resistant to poly
I:C-induced apoptosis, suggesting that the hormone sensitivity is
involved in TLR3-mediated apoptosis. These data confirm our previ-
ous results obtained in PC3 cells overexpressing AR that resulted
sensitive to poly I:C-induced apoptosis [15]. Further experiments are
needed to better clarify the mechanistic role of AR in TLR3-mediated
apoptosis.
Chin et al. previously showed that anticancer activity of poly I:C in
murine PCa cells (TRAMP-C2) subcutaneously engrafted in syngenic
mice is mediated by immune cells, in particular NK cells [36]. Con-
versely, Galli et al. demonstrated that poly I:C treatment reduced
tumour growth only in combined therapy with retinoic acid in andro-
gen-resistant human PCa in in vivo models [10]. Our data demon-
strate that poly I:C treatment, as a single therapeutic agent, markedly
reduces the growth of LNCaP cells in vivo through a direct and there-
fore not immuno-mediated apoptotic effect on PCa cells. This new
evidence highlights the possible application of poly I:C-based therapy
for androgen-sensitive PCa, consistent with data obtained by Salaun
et al. in breast cancer and melanoma. In fact, they demonstrated the
anticancer efficacy of dsRNA treatment on human breast cancer and
melanoma cells engrafted in immune-compromised mice. They also
showed that treatment of breast cancer patients with dsRNA is asso-
ciated with a reduction of metastatic relapse only in TLR3 positive
tumours [11].
Our immunohistochemical study confirmed a reduction of the
proliferative marker Ki-67 and an increase in cleaved caspase 3 stain-
ing in LNCaP xenografts treated with poly I:C. Moreover, poly I:C
treatment significantly increased PSA expression in tumour cell and
massively reduced anti-CXCR4 staining. The stromal derived factor-1
(SDF-1)/CXCR4 axis is associated with tumour aggressiveness and
Fig. 8 Expression of TLR3 and IRF-3 in normal prostate and prostate
cancers. Human prostate biopsies were immune-stained as indicated. In
normal glands, basal cells layer cytoplasm staining of TLR3 and diffuse
faint granular cytoplasm distribution of IRF-3 were detected. Immuno-
staining of TLR3 and IRF-3 in increasing Gleason score PCa are shown
(original magnification 4009).
Table 1 TLR3 and IRF-3 expression in human prostate adenocarcinomas
No. of positive cases*
% positive cells of
G1 adenocarcinomas†
% positive cells of
G2 adenocarcinomas†
% positive cells of
G3 adenocarcinomas†
TLR3 cytoplasm staining 26/30 48 (23–100) 79 (28–100) 83 (22–100)
IRF-3 cytoplasm staining 29/30 72 (35–100) 86 (43–100) 95 (45–100)
*10 cases for every grade where immunostained with TLR3 and IRF-3 antibodies by using conventional immunohistochemistry: G1
(4 tumours = Gleason 3 + 2; 6 tumours = Gleason 3 + 3), G2 (10 tumours = Gleason 3 + 4); G3 (4 tumours = Gleason 4 + 4;
3 tumours = Gleason 4 + 5; 3 tumours = Gleason 5 + 5).
†Results are reported as percentage mean (range) of positive tumour cells.
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metastasis in PCa. Taken together these data suggest a possible role
of poly I:C as differentiating agent. IHC also showed that poly I:C
treatment reduced VEGF staining in LNCaP-derived tumours and
angiogenesis in vivo supporting previous evidence showing that the
activation of TLR3 signalling suppresses angiogenesis both in vitro
and in vivo in other models [37, 38].
Literature data have shown controversial results in studies of
TLR3 expression in human normal prostate epithelium, benign pros-
tatic hyperplasia and PCa. Gonzalez-Reyes et al. showed that 85% of
the analysed PCa cases were positive for TLR3 expression and that
high levels of TLR3 were associated with biochemical recurrence
[39]. On the other hand, it has been shown that TLR3 and IRF-3
were down-regulated in a subset of human PCa tissues and that
TLR3-downregulation was associated with recurrence, suggesting a
successful immune system escaping strategy for some advanced
cancers [40]. Salaun et al. have previously shown the predictive value
of TLR3 expression in the response of breast cancer patients to
dsRNA-based treatment [11]. Our results show that TLR3 and IRF-3
are expressed in PCa tissues at higher level than in normal human
prostate epithelium, supporting the potential application of poly I:C-
based therapy, alone or in combination with standard anticancer
treatments, for PCa.
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